ArticleFrontiers in cardiovascular medicine2026
Incremental prognostic value of pan-immune-inflammation value in conservatively treated acute myocardial infarction: derivation and MIMIC-IV validation.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immune-inflammatory activation contributes to adverse outcomes after acute myocardial infarction (AMI). the study evaluated whether the pan-immune-inflammation value (PIV) was associated with 6-month all-cause mortality and provided prognostic information beyond conventional clinical predictors. Methods: This retrospective two-cohort study included 2,008 conservatively treated patients with AMI in the derivation cohort and 2,679 patients with AMI from the Medical Information Mart for Intensive Care IV (MIMIC-IV) in an independent evaluation cohort. PIV was prespecified as the primary index, with the systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII) assessed as complementary indices. Associations were examined using multivariable logistic regression. Incremental performance was assessed against a prespecified clinical model, with 1,000-resample bootstrap internal validation and Firth penalized logistic regression. Owing to differences in variable availability, MIMIC-IV analyses used a cohort-specific adjustment model. Results: Within 6 months, 57 patients died in the derivation cohort and 773 died in MIMIC-IV. In the derivation cohort, each 1-standard-deviation increase in log-transformed PIV was independently associated with mortality (odds ratio [OR], 1.56; 95% confidence interval [CI], 1.19-2.04; Conclusion: Higher PIV was independently associated with mortality after AMI across both cohorts, but its incremental discrimination beyond conventional clinical factors was modest and statistically nonsignificant. The MIMIC-IV findings support the reproducibility of the association rather than direct validation of an unchanged prediction model. PIV may therefore be considered a complementary marker rather than a stand-alone risk-stratification tool. Prospective multicenter studies are required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.